Cytokinetics Inc (CYTK) fair value: what the stock is really worth
As of Nov 10, 2026: fair value (intrinsic value) of Cytokinetics Inc stock $30.96, price $56.18, that is 44.9% below the price, quality 16 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range $26.88 – $108.06 · fair‑value band $23.22 – $38.70 · the $56.18 price screens above the $30.96 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Cytokinetics in your weekly email
Every Wednesday you see whether Cytokinetics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
Show moreShow less
The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Stock analysis
Cytokinetics Inc (CYTK) currently trades at $56.18, while our estimate is $30.96, 45% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $23.22 (bear) to $38.70 (bull), the price of $56.18 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Cytokinetics Inc reported revenue of $88.0M in FY2025 versus $70.4M in FY2021, a compound +5.7%/yr. Reported net income was −$785M in FY2025.
Key figures
Market cap $7.4B Mid · P/S ratio 66.0 · EPS (TTM) $−6.02 · Return on equity −572% · Return on assets (EBIT) −39.1% (5-year average) · Operating margin −351% · Revenue (TTM) $113M · Revenue growth (YoY) +23.6%.
What moves the price
The share trades about 36% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −45%, CYTK screens richer than that median.
Fair Value
Bear$23.22Fair Value $30.96Bull$38.70
Price $56.18 · Downside -44.9%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Quality Score breakdown
Overall quality16/100
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Profitability3
How much profit the company makes from its sales and capital
Quality Growth75
Are margins and returns getting better?
Cashflow3
Do the profits arrive as real cash?
Financial strength10
Debt, balance sheet and risk of trouble
Investment20
Does it invest with discipline instead of growing at any price?
Low Volatility68
How calm the share price moves, does not count
Price momentum21
Price momentum of the last 3 to 12 months, does not count
In the last 6 months, 7 officers or directors sold shares worth $25.1M and none bought.
SaleFady Ibraham MalikEVP Research & Development19× since Nov 18, 2025: 71,540 shares, avg. $68.96$4.9MNov 3, 2026
SaleRobert I BlumPresident & CEO, Director17× since Mar 9, 2026: 254,958 shares, avg. $69.11$17.6MNov 2, 2026
SaleRobert E LandryDirector2× since Sep 11, 2026: 2,000 shares, avg. $73.40$146,790Sep 15, 202610b5-1 plan
SaleB Lynne ParshallDirector4× since Nov 19, 2025: 20,000 shares, avg. $67.88$1.4MSep 1, 202610b5-1 plan
SaleAndrew CallosEVP, Chief Commercial Officer22× since Dec 5, 2025: 236,948 shares, avg. $67.62$16.0MAug 31, 2026
SaleSung LeeEVP, Chief Financial Officer5× since Mar 17, 2026: 71,817 shares, avg. $79.31$5.7MJul 1, 2026
SaleEdward M. Kaye MDDirector3× since Nov 11, 2025: 36,172 shares, avg. $67.25$2.4MJun 1, 202610b5-1 plan
SaleJohn T HendersonDirector2× since Dec 2, 2025: 28,750 shares, avg. $72.30$2.1MMay 5, 202610b5-1 plan
SaleWendell WierengaDirector2× since Dec 22, 2025: 24,032 shares, avg. $67.63$1.6MMay 5, 202610b5-1 plan
SaleRobert Arthur HarringtonDirector2,150 shares at $66.80$143,620Dec 1, 202510b5-1 plan
Plus 47 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+376.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.5%
Start year 2020 (pandemic). Over 10 years: +11.9% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.2%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−168.3% (2020) → −695.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks
Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score16 · Bottom 25%
Fair Value upside−44.9% · Bottom 25%
Profitability
Return on equity (12 months)Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets−55.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)23.6% · Above median
Balance sheet
Debt / equityNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/BNegative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months)65.50× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)0· sector 96
DIVIDEND (yield)0· sector 20
VALUE 0: the price sits above our fair-value range.
PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Cytokinetics Inc Fair Value". https://www.fairvalue-calculator.com/stock/CYTK
Frequently asked questions
Is Cytokinetics Inc (CYTK) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $30.96 versus a price of $56.18, about 45% lower (overvalued).
What is the fair value of CYTK?
Our estimate for Cytokinetics Inc is $30.96 (as of Nov 10, 2026), built from audited fundamentals. The current price: $56.18.
What is the quality score of CYTK?
Cytokinetics Inc has a Quality Score of 16/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Cytokinetics Inc (CYTK)?
Our calculated price target is the estimate of $30.96 (as of Nov 10, 2026). Cautious scenario $23.22, optimistic scenario $38.70. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Cytokinetics Inc stock forecast for 2026?
Our estimate puts fair value at $30.96, about 45% lower versus a price of $56.18 (overvalued). Cautious scenario $23.22, optimistic scenario $38.70. The calculation is refreshed regularly with new filings.
What is the revenue of Cytokinetics Inc (CYTK)?
Cytokinetics Inc reported trailing-twelve-month revenue of about $113M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Cytokinetics Inc (CYTK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Cytokinetics Inc it is $30.96 per share (as of Nov 10, 2026), against a price of $56.18.
Is Cytokinetics Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, CYTK trades above its calculated fair value: price $56.18, fair value $30.96, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CYTK?
No. The price is what the market pays today ($56.18); the fair value is what the company's own numbers justify ($30.96). For Cytokinetics Inc the two are $25.22 per share apart. That gap is exactly why we show both numbers side by side.
How much is Cytokinetics Inc worth?
The market values Cytokinetics Inc at about $7.4B (market capitalisation, as of Nov 10, 2026). Per share that is $56.18; our models calculate a fair value of $30.96 per share.
What do the bullish and bearish scenarios say about CYTK?
Our models span a range for Cytokinetics Inc: cautious scenario $23.22, base $30.96, optimistic $38.70 per share (as of Nov 10, 2026, price $56.18). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Cytokinetics Inc (CYTK)?
Balance-sheet figures for Cytokinetics Inc (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 16/100, which measures business quality independently of the share price.
How far is CYTK from its 52-week high?
Cytokinetics Inc trades at $56.18, about 36% below its 52-week high of $87.26 and 5% above the low of $53.69 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $30.96 is for.
Which stocks are comparable to Cytokinetics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Cytokinetics Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $56.18, calculated fair value $30.96 (−45%), Quality Score 16/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Cytokinetics Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Cytokinetics Inc (CYTK)?
The closing price on Nov 10, 2026 was $56.18. Our estimate is $30.96, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Cytokinetics Inc right now?
The price sits above even our optimistic bull case ($38.70). The favourable scenario is already priced in. Weak quality (16/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Cytokinetics Inc
How large is the market capitalisation of Cytokinetics Inc (CYTK)?
The market capitalisation of Cytokinetics Inc is $7.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Cytokinetics Inc (CYTK)?
The price-to-sales ratio of Cytokinetics Inc is 66.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Cytokinetics Inc (CYTK)?
Earnings per share at Cytokinetics Inc are $−6.02. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Cytokinetics Inc (CYTK)?
The return on equity (ROE) of Cytokinetics Inc is −572% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Cytokinetics Inc (CYTK)?
On an EBIT basis the return on assets of Cytokinetics Inc is −39.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Cytokinetics Inc (CYTK)?
The operating margin of Cytokinetics Inc is −351% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Cytokinetics Inc (CYTK)?
Revenue at Cytokinetics Inc is growing +23.6% versus a year earlier (3y avg −2.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Cytokinetics Inc (CYTK) generate?
The free cash flow of Cytokinetics Inc is −$535M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Cytokinetics Inc (CYTK) carry?
The net debt of Cytokinetics Inc is $1.2B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Cytokinetics Inc in the live analysis
One click puts Cytokinetics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 10, 2026
